Previous 10 | Next 10 |
2023-09-23 09:45:00 ET Intellia Therapeutics (NASDAQ: NTLA) and Rocket Pharmaceuticals (NASDAQ: RCKT) are gene-editing biotechs that want to offer what few others can: cures for hereditary afflictions that have so far proved beyond the reach of medical science. But for the m...
2023-09-21 07:30:00 ET Summary Rocket Pharmaceuticals achieves a significant milestone in their RP-A501 therapy for Danon Disease, strengthening their position in the gene therapy industry. RP-A501 aims to restore normal cardiac function and offer a lifetime of benefit to patients...
2023-09-18 07:30:00 ET With Rocket Pharmaceuticals ' (NASDAQ: RCKT) shares surging 38% higher on Sept. 13, it's clear that the stock has its enthusiastic supporters. The rare disease drug developer just announced that the Food and Drug Administration (FDA) gave it the go-ahead t...
2023-09-14 09:40:10 ET Summary Rocket Pharmaceuticals announced yesterday it had reached agreement with the FDA on a potentially pivotal study of in vivo gene therapy candidate RP-A501. The drug candidate has faced a long journey to get to this point - now a historic opportunity a...
2023-09-13 14:16:14 ET Gainers: Avalo Therapeutics ( AVTX ) +56% . ZyVersa Therapeutics ( ZVSA ) +41% . Rocket Pharmaceutical ( RCKT ) +35% . Vigil Neuroscience ( VIGL ) +31% . Aspira Women's Health ( AWH ) +27% . Novo Integr...
2023-09-13 11:56:54 ET Shares of Rocket Pharmaceuticals (NASDAQ: RCKT) were up by more than 36% as of 11 a.m. on Wednesday after the clinical-stage biotech company said late Tuesday that the Food and Drug Administration (FDA) had signed off on its phase 2 pivotal trial for a tre...
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) is one of today's top gainers. The company's shares are currently up 40.31% on the day to $21.45. Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapi...
2023-09-13 10:18:38 ET DENVER, Colo., Sept 13, 2023 ( www.247marketnews.com)- News Rocket Pharmaceuticals Reaches FDA Alignment on Pivotal Phase 2 Trial Design for RP-A501 in Danon Disease AND Rocket Pharmaceuticals Announces Pricing of Public Offering of Common Stock ...
2023-09-13 09:14:10 ET (24/7 MARKET NEWS) – Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) stated, after yesterday’s market close, that it reached alignment with the Food and Drug Administration (FDA) on the global Phase 2 pivotal trial of RP-A501 for Danon Disease, a uniformly fa...
2023-09-13 07:59:44 ET More on Rocket Pharma Seeking Alpha’s Quant Rating on Rocket Pharmaceuticals Historical earnings data for Rocket Pharmaceuticals Financial information for Rocket Pharmaceuticals Rocket Pharmaceuticals: Thriving Gene Therapy With ...
News, Short Squeeze, Breakout and More Instantly...
Rocket Pharmaceuticals Inc. Company Name:
RCKT Stock Symbol:
NASDAQ Market:
Rocket Pharmaceuticals Inc. Website:
2024-06-02 14:18:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the European Commission (EC), based on a positive opinion issued by the Committ...
Long-term KRESLADI TM follow-up data demonstrate survival of 100% in the absence of allogeneic hematopoietic stem cell transplantation (HSCT) from 18 to 45 months with a well-tolerated safety profile in all nine patients with severe LAD-I Previously disclosed results from the global R...